Pasithea Therapeutics Corp. (KTTAW) Retained Earnings (2020 - 2026)

Pasithea Therapeutics has disclosed Retained Earnings across 7 years of filings, most recently posting $128.0 million for Q2 2026.

• In Q2 2026, Retained Earnings rose 77.67% year-over-year to $128.0 million; the TTM figure through Jun 2026 stood at $128.0 million (up 77.67% YoY), while the FY2025 annual figure was $125.2 million, up 94.51% from the prior year.
• Retained Earnings came in at $128.0 million for Q2 2026 at Pasithea Therapeutics, roughly flat from $127.6 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $128.0 million in Q2 2026 to a low of $53.8 million in Q1 2022.
• Average Retained Earnings over 5 years is $72.8 million, with a median of $62.1 million recorded in 2023.
• Year-over-year, Retained Earnings soared 200.16% in 2022 and slipped 5.07% in 2023.
• Over 5 years, Retained Earnings stood at $61.9 million in 2022, then decreased by 5.07% to $58.7 million in 2023, then gained by 9.62% to $64.4 million in 2024, then jumped by 94.51% to $125.2 million in 2025, then advanced by 2.21% to $128.0 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $128.0 million in Q2 2026, $127.6 million in Q1 2026, and $125.2 million in Q4 2025.